Table 6.
Age at PID and at cancer diagnosis, survival, outcome, histology, cancer stage, and cancer treatment in 25 CVID patients with gastric cancer.
| ID | Sex |
Age at PID diagnosis (years) |
Age at cancer diagnosis (years) |
Survival after cancer diagnosis (months) |
Outcome | Histology | Stage | Treatment | Additional cancer | Enteropathy (before cancer diagnosis) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 39 | 40 | 408 | Alive | Early gastric cancer, pT1N0 G1 |
stage I | Gastrectomy (total) | Kaposi sarcoma, colorectal carcinoma | No |
| 2 | F | 25 | 31 | 12 | Deceased (cancer) | Gastric adenocarcinoma, NOS | NA | Chemotherapy, NOS | No | Yes |
| 3 | F | 45 | 45 | 252 | Alive | Gastric adenocarcinoma, NOS | NA | Gastrectomy, NOS | Meningioma | No |
| 4 | F | 67 | 69 | 120 | Deceased (cancer) | Early gastric cancer pT1N0 G2, |
stage I | Gastrectomy (total) | Biliary tract carcinoma |
NA |
| 5 | M | 40 | 49 | 7 | Deceased (cancer) | Gastric adenocarcinoma, NOS | NA | Gastrectomy (total) | No | Yes |
| 6 | M | 27 | 51 | 204 | Alive | Gastric adenocarcinoma, intestinal type pT1N0 G2 |
stage I | Gastrectomy (total) | NHL (duodenal) lymphoma |
No |
| 7 | M | 58 | 74 | 36 | Deceased (cancer) | Gastric adenocarcinoma, intestinal type, PT1, N0, M0 |
stage IA | Gastrectomy (subtotal) | No | Yes |
| 8 | F | 35 | 45 | 144 | Alive | Gastric adenocarcinoma, NOS pT1bN1 G1 | stage IB | Gastrectomy (subtotal) | No | No |
| 9 | M | 67 | 67 | 132 | Alive | Gastric adenocarcinoma, NOS | Gastrectomy (subtotal) | Colorectal carcinoma |
Yes | |
| 10 | F | 32 | 38 | 132 | Alive | Early gastric cancer, pT1N0 G2 | stage I | Gastrectomy (subtotal) | HD | Yes |
| 11 | M | 64 | 67 | 30 | Deceased (cancer) | Gastric adenocarcinoma, intestinal type, PT1, N0, Mx, G3 |
stage I | Gastrectomy (subtotal), Chemotherapy (lederfolin, xeloda, 5-fluorouracil) | No | Yes |
| 12 | M | 69 | 75 | 24 | Deceased (cancer) | Gastric adenocarcinoma, NOS | NA | Supportive | No | Yes |
| 13 | F | 35 | 68 | 12 | Deceased (cancer) | Gastric Adenocarcinoma, G3 | NA | Supportive | NHL | Yes |
| 14 | F | 27 | 38 | 9 | Deceased (cancer) | Gastric adenocarcinoma, NOS | NA | Supportive | No | NA |
| 15 | M | 30 | 47 | 12 | Deceased (cancer) | Gastric adenocarcinoma, NOS | stage IIIB | Chemotherapy, NOS | No | Yes |
| 16 | M | 40 | 40 | 84 | Alive | Multifocal Gastric Adenocarcinoma pT2bN0 G3 CMV+ |
stage IB | Gastrectomy (total, two-step) | No | No |
| 17 | M | 59 | 68 | 12 | Deceased (cancer) | Gastric adenocarcinoma, NOS | NA | Supportive | No | Yes |
| 18 | M | 36 | 48 | 11 | Deceased (respiratory failure) | Gastric adenocarcinoma, NOS | NA | Chemotherapy, NOS | No | NA |
| 19 | M | 18 | 40 | 15 | Deceased (cancer) | Gastric adenocarcinoma, intestinal type pT3N3bMx G3 |
stage IIIC | Gastrectomy (total), Chemotherapy (platinum/5-fluorouracil) | No | Yes |
| 20 | F | 43 | 64 | 24 | Deceased (cachexia, meningitis) | Gastric adenocarcinoma, intestinal type pT3N2 G3 | stage IIIA | Gastrectomy (subtotal), + Capecitabine | No | No |
| 21 | M | 22 | 30 | 8 | Deceased (cancer) | Gastric adenocarcinoma, NOS | stage IV | Supportive | No | No |
| 22 | M | 29 | 40 | 7 | Deceased (cancer) | Gastric adenocarcinoma, NOS | stage IV | Chemotherapy, NOS | No | Yes |
| 23 | M | 49 | 51 | 15 | Alive | Multifocal gastric adenocarcinoma, intestinal type, pT1pN0 G3 |
stage I | Gastrectomy (total, two-step) | No | No |
| 24 | M | 47 | 50 | 14 | Alive | Early gastric cancer, intestinal type, pT1bNx G3 |
stage I | Gastrectomy | No | No |
| 25 | F | 46 | 59 | 6 | Deceased (cancer) | Gastric adenocarcinoma G3 |
stage IV | Chemotherapy (epirubicine, platinum, 5-fluorouracil) | No | Yes |
NOS, not otherwise specified; NA, not available M, Males, F, Females; NHL, Non-Hodgkin lymphoma; HD, Hodgkin disease.